Veeda Clinical Research files DRHP for Rs 831 crore IPO
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
Subscribe To Our Newsletter & Stay Updated